 |
|
|
| |
FOLLOW-UP OF SVR DURABILITY AND VIRAL RESISTANCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH TELAPREVIR-BASED REGIMENS: INTERIM ANALYSIS OF THE EXTEND STUDY
|
| |
| |
Reported by Jules Levin
Asian Pacific Association for the Study of the Liver (APASL), Taipei, Taiwan, February 16-19, 2012
Camilla S. Graham1*, Kenneth E. Sherman2, Mark S. Sulkowski3, Fabien Zoulim4, Alfredo Alberti5, Lee-Jen Wei6, James C. Sullivan1, Tara L. Kieffer1, Emily C. Martin1, Sandra De Meyer7, Stefan Zeuzem8; Institutional Author: EXTEND Study Team
Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States. 2. University of Cincinnati College of Medicine, Cincinnati, OH, United States. 3. Johns Hopkins University School of Medicine, Baltimore, MD, United States. 4. INSERM Unit 271, Lyon, France. 5. University of Padova, Padova, Italy. 6. Harvard School of Public Health, Boston, MA, United States. 7. Janssen Infectious Diseases BVBA, Beerse, Belgium. 8. Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany.
|
| |
|
|
|
|
|
